Skip to content
Disclosery

Versant Venture Management, LLC

Follow

13F filer, CIK 1560009, San Francisco, CA

Versant Venture Management, LLC reported $162,612,689 across 8 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-347068

Period
2026-06-30
Reported value
$163M
Holdings
8
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
JBIOreduced-534,037-$11.9M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001193125-26-347068, largest first. % of portfolio is the value over $162,612,689, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 5,652,922 shares; 2025Q1: 5,652,922 shares; 2025Q2: 5,652,922 shares; 2025Q3: 5,652,922 shares; 2025Q4: 4,382,687 shares; 2026Q1: 3,180,780 shares; 2026Q2: 3,180,780 shares 3,180,780$77M47.34%0Timeline
IPSCCENTURY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 12,166,109 shares; 2026Q2: 12,166,109 shares 12,166,109$29.8M18.33%0Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,525,820 shares; 2025Q3: 1,525,820 shares; 2025Q4: 1,525,820 shares; 2026Q1: 1,525,820 shares; 2026Q2: 991,783 shares 991,783$22M13.55%-534,037Timeline
LENZLENZ THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,656,888 shares; 2025Q4: 2,656,888 shares; 2026Q1: 2,656,888 shares; 2026Q2: 2,656,888 shares 2,656,888$15.1M9.28%0Timeline
CTNMCONTINEUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 918,163 shares; 2024Q4: 918,163 shares; 2025Q1: 918,163 shares; 2025Q2: 542,628 shares; 2025Q3: 542,628 shares; 2025Q4: 542,628 shares; 2026Q1: 542,628 shares; 2026Q2: 542,628 shares 542,628$8.89M5.47%0Timeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 498,558 shares; 2024Q4: 498,558 shares; 2025Q1: 498,558 shares; 2025Q2: 498,558 shares; 2025Q3: 148,831 shares; 2025Q4: 148,831 shares; 2026Q1: 148,831 shares; 2026Q2: 148,831 shares 148,831$8.12M4.99%0Timeline
SKYESKYE BIOSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,007,704 shares; 2024Q4: 2,007,704 shares; 2025Q1: 2,007,704 shares; 2025Q2: 2,007,704 shares; 2025Q3: 2,007,704 shares; 2025Q4: 2,007,704 shares; 2026Q1: 2,007,704 shares; 2026Q2: 2,007,704 shares 2,007,704$1.39M0.86%0Timeline
Tempest Therapeutics, Inc.Tempest Therapeutics, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 3,507,055 shares; 2025Q1: not reported; 2025Q2: 269,772 shares; 2025Q3: 269,772 shares; 2025Q4: 269,772 shares; 2026Q1: 269,772 shares; 2026Q2: 269,772 shares 269,772$299K0.18%0

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-347068 base2026-08-12acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001193125-26-347068 Quarter ended 2026-06-302026-08-12acceptance time not in the bulk data set
13F-HR 0001193125-26-206555 Quarter ended 2026-03-312026-05-05acceptance time not in the bulk data set
13F-HR 0001193125-26-048719 Quarter ended 2025-12-312026-02-12acceptance time not in the bulk data set
13F-HR 0001193125-25-274459 Quarter ended 2025-09-302025-11-10acceptance time not in the bulk data set
13F-HR 0000950123-25-007471 Quarter ended 2025-06-302025-08-11acceptance time not in the bulk data set
13F-HR 0000950123-25-004223 Quarter ended 2025-03-312025-05-07acceptance time not in the bulk data set
13F-HR 0000950123-25-001612 Quarter ended 2024-12-312025-02-12acceptance time not in the bulk data set
13F-HR 0000950123-24-010733 Quarter ended 2024-09-302024-11-08acceptance time not in the bulk data set
13F-HR 0000950123-24-007328 Quarter ended 2024-06-302024-08-07acceptance time not in the bulk data set
13F-HR 0000950123-24-003797 Quarter ended 2024-03-312024-05-03acceptance time not in the bulk data set
13F-HR 0000950123-24-001156 Quarter ended 2023-12-312024-02-08acceptance time not in the bulk data set
13F-HR 0000950123-23-009395 Quarter ended 2023-09-302023-11-03acceptance time not in the bulk data set
13F-HR 0000950123-23-007098 Quarter ended 2023-06-302023-08-09acceptance time not in the bulk data set
13F-HR 0000950123-23-004367 Quarter ended 2023-03-312023-05-11acceptance time not in the bulk data set
13F-HR 0000950123-23-001275 Quarter ended 2022-12-312023-02-09acceptance time not in the bulk data set
13F-HR 0000950123-22-011472 Quarter ended 2022-09-302022-11-10acceptance time not in the bulk data set
13F-HR 0000950123-22-008452 Quarter ended 2022-06-302022-08-11acceptance time not in the bulk data set
13F-HR 0000950123-22-005030 Quarter ended 2022-03-312022-05-10acceptance time not in the bulk data set
13F-HR 0000950123-22-001851 Quarter ended 2021-12-312022-02-11acceptance time not in the bulk data set
13F-HR 0000950123-21-014984 Quarter ended 2021-09-302021-11-12acceptance time not in the bulk data set
13F-HR 0000950123-21-010561 Quarter ended 2021-06-302021-08-12acceptance time not in the bulk data set
13F-HR 0000950123-21-005457 Quarter ended 2021-03-312021-05-07acceptance time not in the bulk data set
13F-HR 0000950123-21-002373 Quarter ended 2020-12-312021-02-16acceptance time not in the bulk data set
13F-HR 0000950123-20-011532 Quarter ended 2020-09-302020-11-12acceptance time not in the bulk data set
13F-HR 0001104659-20-084768 Quarter ended 2020-06-302020-07-20acceptance time not in the bulk data set
13F-HR 0001104659-20-052226 Quarter ended 2020-03-312020-04-28acceptance time not in the bulk data set
13F-HR 0001104659-20-005491 Quarter ended 2019-12-312020-01-21acceptance time not in the bulk data set
13F-HR 0001104659-19-053357 Quarter ended 2019-09-302019-10-08acceptance time not in the bulk data set
13F-HR 0001104659-19-039996 Quarter ended 2019-06-302019-07-12acceptance time not in the bulk data set
13F-HR 0001104659-19-020144 Quarter ended 2019-03-312019-04-05acceptance time not in the bulk data set
13F-HR 0001104659-19-002754 Quarter ended 2018-12-312019-01-22acceptance time not in the bulk data set
13F-HR 0001104659-18-060749 Quarter ended 2018-09-302018-10-05acceptance time not in the bulk data set
13F-HR 0001104659-18-045045 Quarter ended 2018-06-302018-07-13acceptance time not in the bulk data set
13F-HR 0001104659-18-030300 Quarter ended 2018-03-312018-05-03acceptance time not in the bulk data set
13F-HR 0001104659-18-003973 Quarter ended 2017-12-312018-01-25acceptance time not in the bulk data set
13F-HR 0001104659-17-062084 Quarter ended 2017-09-302017-10-13acceptance time not in the bulk data set
13F-HR 0001104659-17-048730 Quarter ended 2017-06-302017-08-02acceptance time not in the bulk data set
13F-HR 0001104659-17-022191 Quarter ended 2017-03-312017-04-07acceptance time not in the bulk data set
13F-HR 0001104659-17-002761 Quarter ended 2016-12-312017-01-18acceptance time not in the bulk data set
13F-HR 0001104659-16-151423 Quarter ended 2016-09-302016-10-24acceptance time not in the bulk data set
13F-HR 0001104659-16-135018 Quarter ended 2016-06-302016-07-28acceptance time not in the bulk data set
13F-HR/A 0001104659-16-118185 Quarter ended 2015-12-312016-05-05acceptance time not in the bulk data set
13F-HR 0001104659-16-113751 Quarter ended 2016-03-312016-04-25acceptance time not in the bulk data set
13F-HR 0001104659-16-095427 Quarter ended 2015-12-312016-02-10acceptance time not in the bulk data set
13F-HR 0001104659-15-073439 Quarter ended 2015-09-302015-10-28acceptance time not in the bulk data set
13F-HR 0001104659-15-051249 Quarter ended 2015-06-302015-07-15acceptance time not in the bulk data set
13F-HR 0001104659-15-029755 Quarter ended 2015-03-312015-04-23acceptance time not in the bulk data set
13F-HR/A 0001104659-15-029709 Quarter ended 2014-12-312015-04-23acceptance time not in the bulk data set
13F-HR/A 0001104659-15-029151 Quarter ended 2014-12-312015-04-22acceptance time not in the bulk data set
13F-HR 0001104659-15-025167 Quarter ended 2014-12-312015-04-02acceptance time not in the bulk data set